Aratana Therapeutics, Inc. (PETX) Lifted to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) from a hold rating to a buy rating in a report issued on Thursday morning. They currently have $7.75 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. “
PETX has been the topic of a number of other reports. ValuEngine lowered shares of Aratana Therapeutics from a sell rating to a strong sell rating in a research note on Friday, September 1st. Jefferies Group LLC reiterated a buy rating and set a $8.00 price target on shares of Aratana Therapeutics in a research note on Friday, November 3rd. BidaskClub lowered shares of Aratana Therapeutics from a hold rating to a sell rating in a research note on Tuesday, August 1st. Finally, Lake Street Capital dropped their price target on shares of Aratana Therapeutics from $15.00 to $10.00 and set a buy rating on the stock in a research note on Friday, August 25th. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $8.19.
Shares of Aratana Therapeutics (PETX) traded up $0.15 during trading on Thursday, hitting $7.05. 420,400 shares of the stock were exchanged, compared to its average volume of 392,928. Aratana Therapeutics has a twelve month low of $4.97 and a twelve month high of $8.63. The company has a current ratio of 3.42, a quick ratio of 3.08 and a debt-to-equity ratio of 0.26.
Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The business had revenue of $6.16 million for the quarter, compared to analyst estimates of $6.47 million. During the same period in the previous year, the business posted ($0.38) earnings per share. The business’s revenue was up 1440.0% compared to the same quarter last year. equities analysts anticipate that Aratana Therapeutics will post -1.04 earnings per share for the current fiscal year.
In other Aratana Therapeutics news, insider Peter Steven St sold 50,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $6.24, for a total transaction of $312,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Brent Standridge sold 10,000 shares of the company’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $6.11, for a total transaction of $61,100.00. Following the transaction, the chief operating officer now owns 70,267 shares in the company, valued at $429,331.37. The disclosure for this sale can be found here. Insiders have sold 70,000 shares of company stock worth $435,600 over the last 90 days. 5.20% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. American International Group Inc. grew its position in Aratana Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,354 shares during the period. Janney Montgomery Scott LLC grew its position in Aratana Therapeutics by 7.9% during the second quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 1,200 shares during the period. Metropolitan Life Insurance Co. NY grew its position in Aratana Therapeutics by 17.9% during the first quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 3,883 shares during the period. Voya Investment Management LLC grew its position in Aratana Therapeutics by 22.7% during the second quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 3,610 shares during the period. Finally, Ray Gerald L & Associates Ltd. grew its position in Aratana Therapeutics by 0.8% during the second quarter. Ray Gerald L & Associates Ltd. now owns 24,100 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 200 shares during the period. Institutional investors own 73.39% of the company’s stock.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.